Category: NASDAQ News

Shineco, Inc. (NASDAQ: TYHT) Enters into Strategic Cooperation Agreement with Regional People’s Government for Construction of Industrial Hemp Planting Base

BEIJING, April 4, 2019 /PRNewswire/ — Shineco, Inc. (“Shineco” or the “Company”;NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and various health and well-being focused plant-based products in China, announced today that the Company, through its wholly owned subsidiary Tenjove NewHemp Biotech Co., Ltd. (“TNB”), entered into a strategic cooperation agreement (the “Agreement”) with […]

Continue Reading

SANGAMO AND PFIZER ANNOUNCE PHASE 1/2 INTERIM DATA FOR INVESTIGATIONAL HEMOPHILIA A GENE THERAPY

EIGHT PATIENTS TREATED WITH SB-525 GENE THERAPY SHOWED DOSE-DEPENDENT INCREASES IN FVIII ACTIVITY, WITH THE TWO PATIENTS TREATED WITH THE 3E13 VG/KG DOSE REACHING NORMAL FVIII LEVELS SAFETY MONITORING COMMITTEE RECOMMENDED EXPANSION OF THE 3E13 VG/KG DOSE COHORT Tuesday, April 2, 2019 – 7:00am EDT BRISBANE, Calif. & Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic […]

Continue Reading

ADMA Boologics (NASDAQ: ADMA) Announces FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in Adults and Adolescents (12 to 17 Years of Age) FDA Approval Triggers Funding up to $27.5M from Existing Credit Facility with Perceptive Advisors RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2019 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) […]

Continue Reading

Ziopharm Oncology (ZIOP) Receives FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for Treatment of Recurrent Glioblastoma

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. “Recurrent glioblastoma multiforme […]

Continue Reading

Village Farms International’s (TSX: VFF) (NASDAQ: VFF) Pure Sunfarms Doubles Targeted Annual Production to 150,000 Kilograms by Exercising its Option on Village Farms-Owned 1.1 Million Square Foot Delta 2 Greenhouse Facility

VANCOUVER, April 1, 2019 /PRNewswire/ – Village Farms International, Inc. (“Village Farms” or the “Company”)  (TSX: VFF) (NASDAQ: VFF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has exercised its option on the existing 1.1 million square foot Delta 2 greenhouse facility currently owned by Village Farms in Delta, British Columbia.  The […]

Continue Reading

Phio and Glycostem (NASDAQ:PHIO) to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

MARLBOROUGH, Mass., March 28, 2019 /PRNewswire/ — Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio’s self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem’s proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with […]

Continue Reading

How The African Cannabis Market Could Reach $7.1B By 2023

In the global cannabis landscape, Africa is an overlooked market. This is due to a number of factors, such as the illegality of the plant across the continent and the poor economic conditions that many African countries face. Africa has the potential to become an enormous cannabis market due to the large population and favorable climate that […]

Continue Reading

Cronos Group Inc. Announces Fourth Quarter 2018 and Full Year 2018 Results

Closed C$2.4 Billion Strategic Growth Investment from Altria Group, Inc. Completed first harvest in Peace Naturals expansion to Building 4 Launched Two Recreational Brands: COVE(TM) and Spinach(TM) Announced Landmark Partnership with Ginkgo Bioworks to Produce Cultured Cannabinoids Became first Pure Play Cannabis Company to list on a Major U.S. Exchange Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON.TO) […]

Continue Reading

Aldeyra Therapeutics (NASDAQ: ALDX) Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations – Key secondary endpoint of clinically relevant two-point ocular itch score improvement achieved for both tested reproxalap concentrations – Company closed on $60 million term loan facility LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a […]

Continue Reading

Immutep (NASDAQ: IMMP) Announces United States Patent Grant for Eftilagimod Alpha in Cancer

SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 10,232,038) entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the […]

Continue Reading

Facebook

Would you like to stay up to date with the latest small cap news?  Enter your email.